Gallbladder cancer: adjuvant CRT extends survival in node-positive disease

  • Sci Rep

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adjuvant chemoradiotherapy (CRT) is associated with reduced recurrence and better survival in lymph node-positive gallbladder cancer.
  • No benefit observed in node-negative patients.

Why this matters

  • Previous studies have combined gallbladder and extra- and intrahepatic bile duct cancer and patients undergoing surgery with noncurative intent.

Study design

  • Retrospective analysis of patients with gallbladder cancer who underwent resection with curative intent (n=151).
  • Funding: National Cancer Center.

Key results

  • 64.9% received adjuvant therapy (25.8% chemotherapy, 39.1% CRT) and 35.1% received no adjuvant therapy.
  • In T2-3N0M0 stage disease, adjuvant therapy had no effect on 5-year locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), or OS.
  • In patients with T2-3N1-2M0 disease, adjuvant CRT was associated with better outcomes than no adjuvant therapy or chemotherapy:
    • Locoregional recurrence (11.4%, 78.1%, and 68.4%, respectively; P<.001>
    • Distant recurrence (42.8%, 73.9%, and 66.7%, respectively; P=.044).
    • LRFS (82.1%, 19.0%, and 26.8%; P<.05>
    • RFS (53.3%, 11.6%, and 16.7%; P<.05>
    • OS (64.0%, 4.3%, and 22.7%; P<.05>

Limitations

  • Retrospective analysis.
  • Single institution.
  • Korean population.